Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995).
Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201-995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms.
Lehnert
H
H
Department of Endocrinology, University of Mainz, West Germany.
Beyer
J
J
Weber
P
P
Krause
U
U
Schrezenmeir
J
J
D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D005502:Food; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D015282:Octreotide